Leukemia inhibitory factor signaling modulates both central nervous system demyelination and myelin repair

GLIA

Volumn 56, Issue 6, 2008, Pages 686-698

  Marriott, Mark P ^a   Emery, Ben ^b   Cate, Holly S ^a   Binder, Michele D ^a   Kemper, Dennis ^a   Wu, Qizhu ^a   Kolbe, Scott ^a   Gordon, Ian R ^a   Wang, Hong ^a   Egan, Gary ^a   Murray, Simon ^a   Butzkueven, Helmut ^a   Kilpatrick, Trevor J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Cuprizone; LIF; Myelin; Oligodendrocyte; Oligodendrocyte progenitor; Remyelination

Indexed keywords

CHELATING AGENT; COPPER; CUPRIZONE; LEUKEMIA INHIBITORY FACTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR; 4',6 DIAMIDINO 2 PHENYLINDOLE; DIAGNOSTIC AGENT; GLIAL FIBRILLARY ACIDIC PROTEIN; INDOLE DERIVATIVE; LIF PROTEIN, MOUSE; MYELIN PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEMYELINATION; DRUG EFFICACY; KNOCKOUT MOUSE; MOUSE; NEUROMODULATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OLIGODENDROGLIA; PHENOTYPE; PRIORITY JOURNAL; REMYELINIZATION; SIGNAL TRANSDUCTION; STEM CELL; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DBA MOUSE; DEMYELINATING DISEASE; DISEASE MODEL; DRUG EFFECT; FEMALE; GENETICS; HOSPITALIZATION; MALE; METABOLISM; METHODOLOGY; MOUSE MUTANT; MYELIN SHEATH; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSIOLOGY; WOUND HEALING;

ANALYSIS OF VARIANCE; ANIMALS; CUPRIZONE; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; INDOLES; LEUKEMIA INHIBITORY FACTOR; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; MYELIN PROTEINS; MYELIN SHEATH; OLIGODENDROGLIA; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 45549098045     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.20646     Document Type: Article

References (30)

1. Bakker DA, Ludwin SK. 1987. Blood-brain barrier permeability during Cuprizone-induced demyelination. Implications for the pathogenesis of immune-mediated demyelinating diseases. J Neurol Sci 78:125-137.
2. Barnett MH, Prineas JW. 2004. Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann Neurol 55:458-468.
3. Barres BA, Schmid R, Sendnter M, Raff MC. 1993. Multiple extracellular signals are required for long-term oligodendrocyte survival. Development 118:283-295.
4. Blakemore WF, Keirstead HS. 1999. The origin of remyelinating cells in the central nervous system. J Neuroimmunol 98:69-76.
5. Bugga L, Gadient RA, Kwan K, Stewart CL, Patterson PH. 1998. Analysis of neuronal and glial phenotypes in brains of mice deficient in leukemia inhibitory factor. J Neurobiol 36:509-524.
6. Butzkueven H, Emery B, Cipriani T, Marriott MP, Kilpatrick TJ. 2006. Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss. Glia 53:696-703.
7. Butzkueven H, Zhang JG, Soilu-Hanninen M, Hochrein H, Chionh F, Shipham KA, Emery B, Turnley AM, Petratos S, Ernst M, Bartlett PF, Kilpatrick TJ. 2002. LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat Med 8:613-619.
8. Chang A, Nishiyama A, Peterson J, Prineas J, Trapp BD. 2000. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci 20:6404-6412.
9. Charil A, Filippi M. 2007. Inflammatory demyelination and neurodegeneration in early multiple sclerosis. J Neurol Sci 259:7-15.
10. Emery B, Cate HS, Marriott M, Merson T, Binder MD, Snell C, Soo PY, Murray S, Croker B, Zhang JG, Alexander WS, Cooper H, Butzkueven H, Kilpatrick TJ. 2006. Suppressor of cytokine signaling 3 limits protection of leukemia inhibitory factor receptor signaling against central demyelination. Proc Natl Acad Sci USA 103:7859-7864.
11. Escary JL, Perreau J, Dumenil D, Ezine S, Brulet P 1993. Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation. Nature 363:361-364.
12. Gadient RA, Patterson PH. 1999. Leukemia inhibitory factor, Interleukin 6, and other cytokines using the GP130 transducing receptor: Roles in inflammation and injury. Stem Cells 17:127-137.
13. Haas CA, Hofmann HD, Kirsch M. 1999. Expression of CNTF/LIF-receptor components and activation of STAT3 signaling in axotomized facial motoneurons: Evidence for a sequential postlesional function of the cytokines. J Neurobiol 41:559-571.
14. Linker RA, Maurer M, Gaupp S, Martini R, Holtmann B, Giess R, Rieckmann P, Lassmann H, Toyka KV, Sendtner M, Gold R. 2002. CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation. Nat Med 8:620-624.
15. Ludwin SK. 1978. Central nervous system demyelination and remyelination in the mouse: an ultrastructural study of cuprizone toxicity. Lab Invest 39:597-612.
16. Maier K, Rau CR, Storch MK, Sattler MB, Demmer I, Weissert R, Taheri N, Kuhnert AV, Bahr M, Diem R. 2004. Ciliary neurotrophic factor protects retinal ganglion cells from secondary cell death during acute autoimmune optic neuritis in rats. Brain Pathol 14:378-387.
17. Mason JL, Jones JJ, Taniike M, Morell P, Suzuki K, Matsushima GK. 2000. Mature oligodendrocyte apoptosis precedes IGF-1 production and oligodendrocyte progenitor accumulation and differentiation during demyelination/remyelination. J Neurosci Res 61:251-262.
18. Mason JL, Langaman C, Morell P, Suzuki K, Matsushima GK. 2001. Episodic demyelination and subsequent remyelination within the murine central nervous system: changes in axonal calibre. Neuropathol Appl Neurobiol 27:50-58.
19. Matsushima GK, Morell P. 2001. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11:107-116.
20. McMahon EJ, Suzuki K, Matsushima GK. 2002. Peripheral macrophage recruitment in cuprizone-induced CNS demyelination despite an intact blood-brain barrier. J Neuroimmunol 130:32-45.
21. Merkler D, Boretius S, Stadelmann C, Ernsting T, Michaelis T, Frahm J, Bruck W. 2005. Multicontrast MRI of remyelination in the central nervous system. NMR Biomed 18:395-403.
22. Miller RG, Petajan JH, Bryan WW, Armon C, Barohn RJ, Goodpasture JC, Hoagland RJ, Parry GJ, Ross MA, Stromatt SC. 1996. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann Neurol 39:256-260.
23. Nishiyama A, Yu M, Drazba JA, Tuohy VK. 1997. Normal and reactive NG2+ glial cells are distinct from resting and activated microglia. J Neurosci Res 48:299-312.
24. Pan W, Kastin AJ, Brennan JM. 2000. Saturable entry of leukemia inhibitory factor from blood to the central nervous system. J Neuroimmunol 106:172-180.
25. Plant SR, Arnett HA, Ting JP. 2005. Astroglial-derived lymphotoxin-alpha exacerbates inflammation and demyelination, but not remyelination. Glia. 49:1-14.
26. Prineas JW, Kwon EE, Cho ES, Sharer LR. 1984. Continual breakdown and regeneration of myelin in progressive multiple sclerosis plaques. Ann NY Acad Sci 436:11-32.
27. Redwine JM, Armstrong RC. 1998. In vivo proliferation of oligodendrocyte progenitors expressing PDGFalphaR during early remyelination. J Neurobiol 37:413-428.
28. Stahl N, Yancopoulos GD. 1994. The tripartite CNTF receptor complex: Activation and signaling involves components shared with other cytokines. J Neurobiol 25:1454-1466.
29. Stankoff B, Aigrot MS, Noel F, Wattilliaux A, Zalc B, Lubetzki C. 2002. Ciliary neurotrophic factor (CNTF) enhances myelin formation: A novel role for CNTF and CNTF-related molecules. J Neurosci 22: 9221-9227.
30. Sugiura S, Lahav R, Han J, Kou SY, Banner LR, de Pablo F, Patterson PH. 2000. Leukaemia inhibitory factor is required for normal inflammatory responses to injury in the peripheral and central nervous systems in vivo and is chemotactic for macrophages in vitro. Eur J Neurosci 12:457-466.